002099
vs
S
Shanghai Composite
002099
Over the past 12 months, Zhejiang Hisoar Pharmaceutical Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +47% compared to the Shanghai Composite's +27% growth.
Stocks Performance
002099 vs Shanghai Composite
Performance Gap
002099 vs Shanghai Composite
Performance By Year
002099 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Zhejiang Hisoar Pharmaceutical Co Ltd
Glance View
Zhejiang Hisoar Pharmaceutical Co., Ltd., a prominent entity in China's pharmaceutical landscape, has carved its niche through the synthesis and distribution of both active pharmaceutical ingredients (APIs) and finished dosage forms. Founded in 1995, the company has steadily expanded its operations to cater to an ever-growing demand for high-quality pharmaceuticals. With a robust research and development wing, Hisoar is involved in crafting APIs that form the backbone of many medications used globally, underpinning its revenue streams with consistent, high-volume production. The firm's strategic focus on generic drug manufacturing enables it to tap into markets requiring cost-effective treatments, effectively balancing innovation with affordability—key pillars of its business model. The company's operations are streamlined through vertically integrated facilities that ensure stringent quality control and efficient supply chain management—a critical factor in the highly regulated pharmaceutical industry. By maintaining oversight from the synthesis of raw materials to the production of finished products, Zhejiang Hisoar reduces reliance on external suppliers, thus enhancing profit margins and reinforcing its market position. Partnerships with international firms further broaden their market outreach, allowing the company to export a significant portion of its products. Through these strategically-aligned moves, Zhejiang Hisoar not only sustains its financial health but also contributes to the wider accessibility of essential drugs, making a considerable impact on global healthcare provisioning.
